Aibo Healthcare (688050): The intraocular lens channel inventory price difference almost completely complements the profitability of the vision care business and has the potential to improve the profitability of the vision care business
Aibo Healthcare (688050): Q3 revenue continues to be high, steady increase in soft mirror production capacity
Aibo Healthcare (688050): Steady growth in performance, steady increase in eyelid business
Aibo Healthcare (688050) 2024 Third Quarterly Report Review: Performance is in line with expectations, and next year's performance can be expected to accelerate
Aibo Healthcare (688050): 2024H1 performance is in line with expectations, optimistic about the company's high multi-wheel drive growth
Aibo Healthcare (688050): Revenue increased 73% year-on-year in the second quarter, and the intraocular lens and contact lens business grew impressive
Aibo Healthcare (688050): Impressive performance of intraocular lenses and contact lenses
Aibo Healthcare (688050): Artificial lens collection volume contact lens business creates a third growth curve
Aibo Healthcare (688050): Q2 performance exceeded expectations, optimistic about high growth in intraocular crystals+contact lens dual-wheel drive
Aibo Healthcare (688050): Rapid crystal growth accelerates release of contact lenses
Aibo Healthcare (688050): Multifocal crystals develop the market, and contact lenses grow steadily and rapidly
Aibo Healthcare (688050): A leading domestic intraocular lens company taps into the blue ocean market for contact lenses
Aibo Healthcare (688050): Rapid growth in main business and product launch to fill domestic gaps
Aibo Healthcare (688050): Revenue has greatly accelerated and the contribution ratio of the contact lens sector has increased
Southwest Securities released a research report on April 22 stating that it gave Aibo Healthcare (688050.SH) a purchase rating. The main reasons for the rating include: 1) the 2023 performance was in line with expectations, and the 2024Q1 performance was
Guohai Securities released a research report on April 21 stating that it gave Aibo Healthcare (688050.SH) a purchase rating. The main reasons for the rating include: 1) the surgical treatment and myopia prevention and control business continues to grow, a
Aibo Healthcare (688050): Maintaining High Growth and Further Enriching Research Projects
Aibo Healthcare (688050): Performance exceeds expectations, rapid expansion of contact lens business
Dongwu Securities released a research report on April 19 stating that it gave Aibo Healthcare (688050.SH) a purchase rating. The main reasons for the rating include: 1) gross margin declined slightly due to changes in revenue structure; 2) the second grow
Aibo Healthcare (688050): Performance exceeds expectations, contact lenses became the second growth curve
No Data
No Data